Grifols, S.A Operating Margin 2012-2025 | GRFS

Grifols, S.A operating margin for the quarter ending June 30, 2025 was 16.96%.

  • Grifols, S.A average operating margin for 2024 was 13.18%, a 8.98% increase from 2023.
  • Grifols, S.A average operating margin for 2023 was 14.48%, a 30.58% decline from 2022.
  • Grifols, S.A average operating margin for 2022 was 20.86%, a 8.95% decline from 2021.

Operating margin can be defined as operating margin measurement of what proportion of a company's revenue is left over after paying for variable costs of production such as wages, raw materials, etc.

Grifols, S.A Operating Margin 2012-2025 | GRFS

  • Grifols, S.A average operating margin for 2024 was 13.18%, a 8.98% increase from 2023.
  • Grifols, S.A average operating margin for 2023 was 14.48%, a 30.58% decline from 2022.
  • Grifols, S.A average operating margin for 2022 was 20.86%, a 8.95% decline from 2021.

Operating margin can be defined as operating margin measurement of what proportion of a company's revenue is left over after paying for variable costs of production such as wages, raw materials, etc.
Related Stocks
Company NameMarket
Cap
Zoetis (ZTS)$68.8B
Chugai Pharmaceutical (CHGCY)$68.7B
Takeda Pharmaceutical (TAK)$48B
Daiichi Sankyo, - (DSNKY)$47.8B
BeOne Medicines - (ONC)$33.8B
Sandoz Group AG (SDZNY)$27.6B
Summit Therapeutics (SMMT)$19.5B
Merck (MKKGY)$16.5B
Shionogi (SGIOY)$14.7B
United Therapeutics (UTHR)$13.8B
Neurocrine Biosciences (NBIX)$13.3B
IPSEN (IPSEY)$11.4B
Orion OYJ (ORINY)$11.3B
Eisai (ESAIY)$9.2B
Madrigal Pharmaceuticals (MDGL)$9.2B
Corcept Therapeutics (CORT)$7.3B
Ionis Pharmaceuticals (IONS)$6.7B
Stevanato Group S.p.A (STVN)$6.7B
Ono Pharmaceutical (OPHLF)$5.7B
Hikma Pharmaceuticals Plc (HKMPF)$5.4B
Soleno Therapeutics (SLNO)$3.5B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.9B
Crinetics Pharmaceuticals (CRNX)$2.8B
NewAmsterdam Pharma (NAMS)$2.8B
Hypermarcas (HYPMY)$2.8B
Catalyst Pharmaceuticals (CPRX)$2.5B
Procaps Group, S.A (PROCF)$2.4B
Centessa Pharmaceuticals (CNTA)$2.3B
Ocular Therapeutix (OCUL)$2.1B
Dyne Therapeutics (DYN)$1.8B